Sector News

Wound repair, custom prosthetics targeted by developers of multi-material bioprinter

June 16, 2023
Life sciences

Researchers have developed a handheld multi-material bioprinter with applications ranging from wound repair to custom prosthetics. The bioprinter, details of which were published in the journal Biofabrication, improves on earlier devices by enabling the printing of multiple materials and giving control over the properties of printed tissues. Printing multiple materials could improve tissue biomimicry and facilitate the simultaneous or sequential dispensing of different materials and cells. Researchers at the University of Victoria and University of Montreal used the device to print multiple cells, drug-releasing meshes and sensors.

Bioprinting technology has advanced over the past decade. In 2016, researchers shared details of a handheld device for surgical printing of adipose stem cells, and in 2020 another team loaded a device with pore-forming bio-ink for in situ wound dressing.

The latest study addresses some of the limitations of those older technologies. A temperature control module supports long-term printing, and print heads that allow the flow of several bio-inks enable multi-material printing, resulting in a device capable of depositing hydrogel fibers and different types of cells such as dermal fibroblasts.

Using the device, the researchers printed directly on artificially created pig skin wounds. Mohsen Akbari, one of the authors of the paper and an associate professor at the University of Victoria in Canada, explained some of the applications in an article from the Institute of Physics’ IOP Publishing. READ MORE

By Nick Paul Taylor


comments closed

Related News

June 8, 2024

Lilly CFO leaves to join Alphabet

Life sciences

Anat Ashkenazi will leave Eli Lilly’s executive suite at the end of July to become CFO and senior vice president of Google and Alphabet. Ashkenazi has been CFO at Lilly since 2021 and originally joined the company in 2001. Over her 23-year career at the Indianapolis-based drugmaker, Ashkenazi also served as controller, CFO of Lilly Research Laboratories and as the finance chief for several global divisions within the company.

June 8, 2024

Edwards Lifesciences to cell Critical Care to BD

Life sciences

Edwards Lifesciences (NYSE: EW) announced it has entered into a definitive agreement to sell its Critical Care product group to BD (Becton, Dickinson and Company), in an all-cash transaction valued at $4.2 billion. With this agreement, Edwards is no longer pursuing the previously announced spin-off of Critical Care.

June 8, 2024

Danaher names Martin Stumpe as chief data and AI officer

Life sciences

The company, which owns diagnostics and life sciences businesses including Beckman Coulter and Cepheid, said the appointment reflects its increasing investment in AI as “a driving force for innovation and productivity.” Danaher is focused on AI by also spending on its internal capabilities and partnering with academic groups.

How can we help you?

We're easy to reach